Published study on Parkinson's drug contradicts previous concerns

02/18/2005 | Los Angeles Times (tiered subscription model)

A study published in the Journal of Neurology, days after Amgen stopped giving its trial GDNF drug to Parkinson's patients in company-supported studies, says the medication led to improved mobility in seven of the 10 patients who received the medicine. The new study's author urged Amgen to reconsider its decision, but an Amgen spokeswoman said she was unaware of the study from the University of Kentucky team.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA